Filing Details

Accession Number:
0001628280-21-019311
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-09-29 21:26:04
Reporting Period:
2021-09-27
Accepted Time:
2021-09-29 21:26:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1504776 Warby Parker Inc. WRBY Ophthalmic Goods (3851) 800423634
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1883345 Harris Neil Blumenthal C/O Warby Parker Inc.
233 Spring Street, 6Th Floor East
New York NY 10013
Co-Chief Executive Officer Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2021-09-27 200,000 $0.00 200,000 No 4 C Indirect By Royal Blue Aries Trust
Class A Common Stock Acquisiton 2021-09-27 200,000 $0.00 200,000 No 4 C Indirect By Tiffany Blue Gemini Trust
Class A Common Stock Disposition 2021-09-29 150,000 $54.04 2,261,167 No 4 S Indirect By JJR WP Holdings LLC
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect By Royal Blue Aries Trust
No 4 C Indirect By Tiffany Blue Gemini Trust
No 4 S Indirect By JJR WP Holdings LLC
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class A Common Stock Class B Common Stock Disposition 2021-09-27 200,000 $0.00 200,000 $0.00
Class A Common Stock Class B Common Stock Disposition 2021-09-27 200,000 $0.00 200,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
200,000 No 4 C Indirect
200,000 No 4 C Indirect
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Class A Common Stock Class B Common Stock $0.00 2,775,394 2,775,394 Direct
Class A Common Stock Class B Common Stock $0.00 1,519,661 1,519,661 Indirect
Class A Common Stock Class B Common Stock $0.00 399,402 399,402 Indirect
Class A Common Stock Class B Common Stock $0.00 800,000 800,000 Indirect
Expiration Date Amount Remaning Holdings Nature of Ownership
2,775,394 2,775,394 Direct
1,519,661 1,519,661 Indirect
399,402 399,402 Indirect
800,000 800,000 Indirect
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.90 to $54.24. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. Mr. Blumenthal disclaims pecuniary interest therein.
  3. Each share of the Issuer's Class B Common Stock is convertible into one share of the Issuer's Class A Common Stock at the option of the holder and has no expiration date.
  4. The Class B Common Stock is convertible at any time at the option of the holder into the Issuer's Class A Common Stock on a one-to-one basis. The Class B Common Stock will automatically convert into shares of the Issuer's Class A Common Stock on a one-to-one basis upon the earlier of (i) transfer of Class B common stock to a person or entity that is not in the transferor's permitted ownership group, (ii) October 1, 2031, (iii) with respect to any Class B common stock held by any person or entity in Neil Blumenthal's permitted ownership group, (A) such time as Neil Blumenthal is removed or resigns from the board of directors, or otherwise ceases to serve as a director, (B) such time as Neil Blumenthal ceases to be either an employee, officer or consultant of the Company or any of its subsidiaries, or (C) the date that is 12 months after the death or disability of Neil Blumenthal,
  5. and (iv) with respect to any Class B common stock held by any person or entity in Dave Gilboa's permitted ownership group, (A) such time as Dave Gilboa is removed or resigns from the board of directors, or otherwise ceases to serve as a director, (B) such time as Dave Gilboa ceases to be either an employee, officer or consultant of the Company or any of its subsidiaries, or (C) the date that is 12 months after the death or disability of Dave Gilboa.